Open AccessOutcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01)
Author(s) -
Trista J. Stankowski-Drengler,
Jessica R. Schumacher,
Bret M. Hanlon,
Devon Livingston-Rosanoff,
K. Van de Walle,
Caprice C. Greenberg,
Lee G. Wilke,
Heather B. Neuman
Publication year - 2020
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-019-07846-2
Subject(s) - medicine , breast cancer , gastroenterology , chemotherapy , hazard ratio , proportional hazards model , stage (stratigraphy) , oncology , cancer , confidence interval , paleontology , biology
Pathologic complete response (pCR) after neoadjuvant chemotherapy has a demonstrated survival advantage; however, outcomes for non-pCR by receptor status are less understood. We sought to evaluate survival and distant recurrence by receptor status for patients with residual stage II/III breast cancer.